Akari Therapeutics Plc (AKTX)
CIK 1541157 · all EDGAR filings →
Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.
Shares outstanding over time
Latest: 91.57B shares as of May 19, 2026 (10-Q).
Cash runway
Going-concern warning
auditor flagged substantial doubt
The company itself flagged going-concern doubt in a filing.
Full breakdown: cash runway tool · source filing →
Warrants
| Tranche | Warrants | Exercise price | Term | Notes |
|---|---|---|---|---|
| Series G Warrants | 19.06B | not tagged | — | — |
Tranches exactly as the company dimensioned them in its 10-Q filed May 19, 2026 →. Groupings can overlap (a “Series E and F” row is not additive with a “Series E” row), so do not sum this column. A tranche the filer did not tag is absent here, not absent from the cap table. DOWN-ROUND = the filer tagged price-protection accounting scoped to that tranche.
Warrants outstanding: 1.7M underlying shares, as reported Mar 31, 2026 (10-Q).
Reported exercise price: $0.18945 (aggregate figure as tagged; individual tranches vary).
Balance-sheet fair value of warrants: $3.2M as of Dec 8, 2020.
Rough fully diluted estimate: 91.57B = 91.57B O/S + 1.7M warrant shares. An estimate, not a filing figure: it ignores converts, options and RSUs, and the two inputs carry different as-of dates.
Convertible notes
| Note | Principal | Carrying | Conv. price | Rate | If converted |
|---|---|---|---|---|---|
| April Two Thousand Twenty Three Convertible Notes | not tagged | — | $0.00102 | 10% | — |
| April Two Thousand Twenty Three Convertible Notes and Warrants Amendment | not tagged | — | $0.000405 | — | — |
| April Two Thousand Twenty Three Peak Bio Convertible Noteholder Warrants | not tagged | — | $0.000405 | — | — |
Notes exactly as the company dimensioned them in its 10-Q filed May 19, 2026 →. Principal is face amount as tagged, not what remains after repurchases unless the filer updated the tag. A note the filer did not dimension is absent here, not absent from the balance sheet; the exhibits stay the ground truth.
Fully diluted build-up
Shares outstanding plus every potential-share instrument the filer tagged in XBRL, each at its own as-of date. An estimate assembled from filed figures, not a filing figure itself.
| Shares outstanding | 91.57B | May 19, 2026 |
| + Series G Warrants (if exercised) | 19.06B | Dec 31, 2025 |
| Fully diluted estimate | 110.62B | +20.8% vs O/S |
Still excluded, because the filer does not tag them in countable form: employee options and RSUs, any instrument living only in exhibit prose, and instruments above missing a share count. Inputs carry different as-of dates, shown per row. Each figure traces to the tranche and note tables above and their cited filings.
Registrations and offerings
Registered offering capacity on live registrations: $60.6Mfrom the structured fee exhibits; registered is not remaining, takedowns are not subtracted
Last 12 months: 6 executed · 8 registered.
Full history and shelf status: offering checker · S-3 shelf checker
Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.
Keep going: float checker · offering calendar · short-squeeze screener · full AKTX workspace